Biotech Pharmaceutical
PepVax has been founded on the foundational understanding that many cancers can be treated via the harnessing the power of the human immune system. The pipeline of the company consists of a DNA viral vaccine construct that is target to tumors that expresses the Melanoma antigen family – A (MAGE-A) antigen.
The company has a pipeline of therapeutics that has a high success probability because our treatment targets patient population medical needs are not being met at this time. Our leading pipeline is a universal vaccine that can be used for any tumor that expresses tumor antigen MAGE-A. This treatment can be targeted to cancers that has a high expression of the MAGE-A antigen including, breast, colon, pancreas, glioblastoma, and esophageal squamous cell carcinomas, for example. The company expects to focus on developing the treatment for triple negative breast cancer.
Our research that will be ongoing is designed to reach human clinical trials and market via the leveraging of the immune system with its ability to treat tumors. The key to our strategies also includes our ability to combine our technology with anti-PD-L1 and/or anti-CTL4. With the potential for positive results of the ongoing pre-clinical stage programs, the next stage would allow the company to viable biotechnology commercial entity.